Figure 6.

Eosinophils are activated upon exposure to virus in vivo (A). FEV₁ of asthma patients before RV16 challenge does not correlate (left) with CD69 expression on BALF eosinophils, whereas they correlate after RV16 challenge (right) (placebo‐ and mepolizumab‐treated groups (Pearson r: −0.55; P = 0.01) and for placebo‐treated group alone (Pearson r: −0.74; P < 0.01)). (b) After RV16 exposure in vivo, eosinophils become more activated (all mild asthmatics (pink; n = 19), placebo (gray; n = 11) and mepolizumab (black; n = 8)). Data are expressed as mean ± SEM. Paired t test or Pearson correlation: ***P < 0.001